Table of Contents

About the Journal

Cardiovascular Pharmacology: Open Access Journal has the increasing role in diagnosis, characterization, therapy of various marked diseases in the field of Cardiovascular Pharmacology. The journal aims to promote international dialogue and collaboration on health issues to improve clinical practice and to expand and deepen the understanding of health and health care.

The journal includes a wide range of fields which mainly deals with Angina, Stroke and all Heart diseases and its pharmacology related to all living organisms.

Cardiovascular Pharmacology: Open Access is a journal that aims to publish the most complete and reliable source of information on the discoveries and current developments as original articles, review articles, case reports, short communications, etc. in all areas of the field and make them available online to the researchers worldwide without any subscriptions.

The Journal provides a unique forum dedicated to scientists to express their research on a wide array of Cardiovascular Pharmacology topics. The Cardiovascular Pharmacology: Open Access Peer Reviewed Journal is proficiently supported by universally prominent Editorial Board members. Cardiovascular Pharmacology: Open Access journal impact factor is mainly calculated based on the number of articles published and cited on a given year.

OMICS International organizes 1000 conferences every year across USA, Europe & Asia with support from 1000 more scientific societies, 400+ symposiums and Publishes 700+Open access journals which contains over 50000 eminent personalities, reputed scientists as Editorial board members.

Cardiovascular Safety Pharmacology

Cardiovascular Pharmacology mainly contributes to the safety profile of potential new drugs and provide pharmacological data that can be used for optimization of further compounds and the ultimate selection of compounds suitable for clinical development.

Cardiovascular Toxicology

Cardiovascular Toxicology deals with the adverse effects on the heart or blood systems which result from exposure to toxic chemicals. It describes safety data of detrimental effects of new cardiovascular drugs.

Cardiovascular Drugs

Cardiovascular Drugs refers to Prescription drugs and medicines for diseases relating to the structure and function of the heart and blood vessels. Studies in these areas include: heart failure, coronary artery disease, high cholesterol, blood clots, circulation disorders, and others.

Cardiac Cachexia

A term for the muscle and weight loss caused by severe heart disease. It is often related to the depressed cardiac output associated with end-stage Heart failure, but it can also occur with severe coronary artery disease.

OMICS International is honoured to invite all the participants to join 2nd International Conference on Cardiovascular Medicine and Cardiac Surgery during March 15-16, 2017 at London, UK. This conference mainly aims to discuss an approach for cardiovascular diseases. It is mainly designed to provide diverse and current education that will keep medical professionals alongside of the issues affecting the diagnosis, treatment of Cardiac disorders and prevention.

*2016 Journal Impact Factor was established by dividing the number of articles published in 2014 and 2015 with the number of times they are cited in 2016 based on Google search and the Scholar Citation Index database. If 'X' is the total number of articles published in 2014 and 2015, and 'Y' is the number of times these articles were cited in indexed journals during 2016 then, impact factor = Y/X